Target therapy in treatment of HER2-positive breast cancer
The breast cancer (BC) wins first place in structure of oncological incidence of the female population around the world. The special place is occupied by tumors with a superfluous expression of HER2 of a factor which is defined at 25–30 % of patients. Interest to suchpatients is defined by an aggres...
Saved in:
Main Authors: | A. S. Belokhvostova, I. A. Smirnova, A. A. Enileeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
Series: | Сибирский онкологический журнал |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/103 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01) -
Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01) -
HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01) -
Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01) -
Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)